Business Context and Reporting Period
This Form 8-K was filed by Syndax Pharmaceuticals, Inc. on February 3, 2021. The report discloses compensation arrangements for named executive officers approved by the Board of Directors on the same date. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation details.
Executive Compensation Details
| Executive | Title | 2020 Cash Bonus | 2021 Base Salary | 2021 Bonus Target | Option Grant (Shares) |
|---|---|---|---|---|---|
| Briggs W. Morrison, M.D. | CEO and Director | $285,260 | $618,563 | 50% | 195,000 |
| Michael A. Metzger | President and COO | $273,980 | $594,104 | 50% | 160,000 |
| Michael L. Meyers, M.D., Ph.D. | SVP, Chief Medical Officer | $172,655 | $450,250 | 40% | 80,000 |
Equity Terms: Options have an exercise price of $21.36 per share (closing price on Feb 3, 2021), a 10-year term, and vest monthly over 48 months.
Material Changes
The filing reports the approval of 2020 cash bonuses and the establishment of 2021 base salaries and bonus targets effective January 1, 2021. Additionally, new stock options were granted to the named executives.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, or specific risk factors beyond the standard disclosure of compensation arrangements.
Investor Verification Checklist
- Verify the total dilution impact of the 435,000 new stock options granted.
- Confirm the company's cash position to ensure it can fund the approved 2020 cash bonuses totaling approximately $732,000.
- Review the 2015 Omnibus Incentive Plan to confirm the availability of shares for these grants.
- Monitor future filings for the actual payout of the 2021 bonus targets based on performance metrics.